drug
pneumococcal vaccine
Preclinicalupdated 6mo agoby Aeolian Biotech LLC
Preclinicalcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying pneumococcal vaccine
- phase2A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
- N/AStructured Review: To Optimise Management and Prevent Harm in COPD
- phase4Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
- phase2Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
- phase3Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
- phase2A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
- phase2A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
News(8)
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 13d ago
- Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surgesVaxcyte's shares {$PCVX} jumped 35% Monday morning after the company announced that its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults, a major step i…endpoints · 1mo ago
- Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine dataThe company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3…biopharma_dive · 1mo ago
- Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, MerckVAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a…biospace · 1mo ago
- STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and moreVaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merckstat · 1mo ago
- STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine marketVaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.stat · 1mo ago
- Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shotsVaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest.fiercebiotech · 1mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that